$BNTX

The Motley Fool on $BNTX (Nov 14, 2026)

AI summary · The Motley Fool

Billion to One counts individual DNA molecules rather than estimating proportions, giving single-molecule precision for tests competitors lack. Quarterly revenue beat consensus by about 50% YoY, diluted EPS more than doubled expectations, and oncology revenue rose 96% to about a $68 million annual rate; it posted a fifth straight positive GAAP operating income. A blood-based minimal residual disease test for all solid tumors launches mid-December, expanding its tumor tests in an administration-estimated $30 billion market; the speaker sees a long growth runway and puts it on the watchlist before end-2026.

BullishHe framed it in years
“4 Stocks to Buy Before the End of 2026!”
The Motley FoolPublished Nov 14 · 6 passages

Playing via YouTube may share device and playback data and use cookies. Privacy Notice · Google Privacy Policy

Jump to any passage

6 passages
16:2619:08

will be the most important to the company and its growth story in the future. One of the interesting things is to talk about the platform technology that Billion to One relies on.

Just to explain why it's a bit more distinctive.

The Billion to One platform works by linking a unique tag to each DNA molecule, enabling it to actually count those molecules rather than estimate their proportion. You can think of it as the difference between weighing a mixed bag of coins to estimate the number of coins in it, versus marking and counting each coin individually.

This precision, that is, precision at the level of a single molecule, is what allows Billion2One to offer these highly accurate diagnostic tests that some established competitors have not yet been able to provide.

They also announced their quarterly results about a week ago, with total revenue exceeding consensus estimates by about 50% year-over-year. Diluted earnings per share were more than double what Wall Street had expected.

Their revenue from prenatal testing increased by 41% year-on-year. Oncology revenues, which are still a smaller but fastest-growing part of the company, have increased by 96% year-on-year, and now reach an annual rate of about $68 million.

They generated approximately $9 million in free cash flow during the quarter. This was the fifth consecutive quarter in which they achieved positive operating income according to generally accepted accounting principles.

They have approximately $562 million in cash and cash equivalents on their balance sheet.

One of the most important things to watch regarding their oncology work is that they have a new test that will be launched in mid-December. This is a test to detect minimal residual disease.

Essentially, this test is designed to detect microscopic traces of cancer that remain after a patient's tumor has been surgically removed. It is a blood-based test only. It is available for all solid tumors from day one.

It will be released here in the next few weeks. This is essential as they work to expand their range of tumor tests.

It's a great job. It's a profitable business. It is a business that continues to see very strong growth across both its prenatal testing and oncology businesses. But for me, the fact that they are launching these premium cancer monitoring products into a broad, accessible market— which the administration estimates to be worth about $30 billion—is in addition to this already validated technology platform.

I think Billion to One has a long way to go to grow, and I think this is definitely a business to put on your watchlist before the end of 2026.

Watchpoints

launch of the blood-based minimal residual disease test for all solid tumors
TickerSays